Abstract

Relevance. The topicality of the work is determined by the wide spread of hypomagnesemia among the people, which makes it necessary to correct it. The aim of the work is to elucidate the cell-mediated response of the thymus mastocytic link to magnesium deficiency and its correction by the mechanoactivated form of magnesium orotate. Materials and Methods . Animals with drug-induced magnesium deficiency (administration of furosemide 30 mg/kg for 14 days) were administered either the initial preparation Magnerot (Magnerot, Vervag Pharma, Germany), or its mechanoactivated form. The level of magnesium in the blood was determined by test systems ARKREY (Japan). The concentration of magnesium in the thymus tissue was determined by the method of emission spectroscopy with inductively coupled (argon) plasma on an atomic emission spectrometer. Density of mastocytes and the indices of degranulation and granulolosis were calculated on paraffin sections of the thymus after coloration with toluidine blue. Results and Discussion . It was shown that furosemide administration the amount of magnesium decreased in the blood (from 1,750,08 to 0,9020,18 mmol/l, p0,05), but increased in the thymus (from 1,60,6 in the control to 3,71,2 mg/l); in the gland tissue, the number of mastocytes of morphotype A decreased and the number of mastocytes of morphotype D, after active degranulation, increased (by 7,1 times, p0,05). The type of mastocyte secretion in hypomagnesemia is represented by the merocrine variant. The administration of the initial magnesium orotate led to an increase in the concentration of magnesium in the blood to 1,150,25 mmol/l, which is 65,7% of the initial level, the amount of magnesium in the thymus remained elevated (3,41,1 mg/l), the number of actively degranulating cells (morphotype D) was increased. Mechanoactivated magnesium orotate restored the concentration of Mg2+ in the blood to 89,1% (1,560,18 mmol/l, p0,05) and decreased in the thymus (to 2,30,7 mg/l), restored the subpopulation of mastocytes saturated with heparin (type A), reduced the number of mastocytes of morphotype D. Conclusion . The mechanoactivated form of magnesium orotate has a normalizing effect on the population of thymic mastocytes, shows pronounced immunomodulatory activity, which allows us to consider it as a potential therapeutic agent for clinical testing in the complex therapy of hypomagnesemia and associated immunodeficiency.

Highlights

  • Mast cells are active participants in the regulation of immune homeostasis, which are given active attention in the scientific literature, including recent years [1,2,3]

  • A variety of reasons [4, 5] is the basis of the immune imbalance in magnesium deficiency, which requires pharmacological correction

  • Magnesium salts of organic acids are the active substances of most drugs used to correct the condition of hypomagnesemia and its consequences

Read more

Summary

Introduction

Mast cells are active participants in the regulation of immune homeostasis, which are given active attention in the scientific literature, including recent years [1,2,3]. Magnesium orotate has three isomeric forms that differ by functional groups: nitrogen- and oxygen-containing groups. These groups determine the participation of the orotate anion in biological and biochemical processes, which is accompanied by different therapeutic effectiveness [6]. An important stage in the study of the properties of new or modified already known and used in the clinic (like magnesium orotate) forms of medicines is the analysis of their immune and/or allergic effects on the body. The aim of the research is to elucidate the cell-mediated reaction of the mast cells of thymus to magnesium deficiency and its correction by the mechanically activated form of magnesium orotate

Objectives
Methods
Results
Full Text
Paper version not known

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call